Dr Mark Verrill
| Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study | 2021 |
|
Dr Mark Verrill
| Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage | 2020 |
|
Anantha Madhavan
Alexander Phillips
Arul Immanuel
Dr Mark Verrill
Professor Michael Griffin
et al. | Surgical management of gastric gastrointestinal tumours: Comparison of local and radical resection | 2018 |
|
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al. | Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide | 2017 |
|
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
et al. | Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance | 2016 |
|
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al. | Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil | 2014 |
|
Dr Mark Verrill
| The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib | 2011 |
|
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al. | Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy | 2011 |
|
Dr Chris Plummer
Dr Mark Verrill
| Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials | 2010 |
|
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al. | Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide | 2010 |
|
Dr Mark Verrill
| Capecitabine and vinorelbine in metastatic breast cancer | 2009 |
|
Dr David Jamieson
Dr Nicola Cresti
Dr Mark Verrill
Professor Alan Boddy
| Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma | 2009 |
|
Dr Chris Plummer
Dr Mark Verrill
| Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk | 2009 |
|
Dr Fathi Azribi
Dr Petra Dildey
Dr John Wilsdon
Dr Mark Verrill
| Imatinib in gastrointestinal stromal tumour (GIST): Northern cancer network experience | 2009 |
|
Professor Ruth Plummer
Professor Alan Boddy
Melanie Griffin
Dr Mark Verrill
| A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies | 2008 |
|
Dr Mark Verrill
Dr Chris Plummer
| DEVELOPMENT AND IMPLEMENTATION OF NEW UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) GUIDELINES FOR PREVENTING AND MANAGING CARDIAC EVENTS WITH TRASTUZUMAB | 2008 |
|
Dr Elizabeth McIntyre
Dr Mark Verrill
Dr Richard Quinton
Professor Simon Pearce
| Lesson of the week: Unrecognised severe hypovitaminosis D | 2008 |
|
Dr Mark Verrill
| UK TACT trial results - does everyone need adjuvant taxanes? | 2008 |
|
Dr Mark Verrill
| A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer | 2007 |
|
Amina Razak
Dr Beate Haugk
Dr Mark Verrill
| Desmoplastic small round-cell tumor of the pancreas | 2007 |
|
Dr Mark Verrill
| Hormonal therapy for postmenopausal breast cancer: the science of sequencing | 2007 |
|
Dr Jo Lee
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Sharon Erb
et al. | Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer | 2007 |
|
Dr Mark Verrill
Dr Steven O'Reilly
| TEXAS (Taxotere (R) EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC | 2007 |
|
Dr Jo Lee
Julieann Sludden
Professor Alan Boddy
Dr Mark Verrill
| Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule. | 2006 |
|
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al. | A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules | 2005 |
|
Professor Jacqueline Rodgers
Dr Rachel Morse
Katherine Kendell
Dr Mark Verrill
| An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer | 2005 |
|
Dr Mark Verrill
| Cost-effectiveness (C-E) of oral ibandronate compared with intravenous (iv) zoledronic acid or iv generic pamidronate in patients with metastatic bone disease from breast cancer in the UK | 2005 |
|
Dr Mark Verrill
Duncan Cameron
| Externally audited results of the international breast cancer dose-intensity study (IBDIS) | 2005 |
|
Dr Mark Verrill
| Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer | 2005 |
|
Dr Mark Verrill
| Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2) | 2005 |
|
Ching Ng
Dr Mark Verrill
Jessica Hodge
| Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer | 2005 |
|
Dr Mark Verrill
| Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study | 2005 |
|
Dr Mark Verrill
Duncan Cameron
| Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial | 2004 |
|
Dr Mark Verrill
| Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I | 2004 |
|
Dr Mark Verrill
| Evidence that durable complete remissions (DCR) of metastatic breast cancer (MBC) following high-dose chemotherapy (HDC) are not artefacts of selection by response: mature results of the International Breast Cancer Dose Intensity Randomised and Pilot Studies (IBDIS-I) | 2004 |
|
Dr Mark Verrill
| Lessons from a positive randomized trial of high-dose chemotherapy in metastatic breast cancer: Learn from our mistakes, build on our successes, drain the bathwater, hold the baby | 2004 |
|
Dr A Stewart
Dr Mark Verrill
| Trilostane, an effective signal transduction inhibitor for advanced ER plus ve and ER-ve post-menopausal breast cancer | 2004 |
|
Dr Mark Verrill
Professor Jacqueline Rodgers
Dr Rachel Morse
Katherine Kendell
| Adjuvant taxane and block sequential anthracycline regimens predict post treatment cognitive morbidity | 2003 |
|
Professor Jacqueline Rodgers
Dr Rachel Morse
Dr Mark Verrill
Katherine Kendell
| Cognitive functioning in women following adjuvant treatment for breast cancer | 2003 |
|
Dr A Stewart
Dr Mark Verrill
| Multi-center clinical trials of trilostane (modrenal) for advanced breast cancer in post-menopausal women | 2003 |
|
Dr Rachel Morse
Professor Jacqueline Rodgers
Dr Mark Verrill
Katherine Kendell
| Neuropsychological functioning following systemic treatment in women treated for breast cancer: A review | 2003 |
|
Dr Mark Verrill
Professor Alan Boddy
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al. | Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors | 2003 |
|
Dr Mark Verrill
| Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma | 2003 |
|
Dr Mark Verrill
| Preliminary results of a phase II study of intravenous vinflunine as second line therapy in patients with metastatic breast cancer after anhracycline-taxane based regimen failure | 2003 |
|
Dr Mark Verrill
| A guideline for the management of gastrointestinal stromal tumour (GIST) | 2002 |
|
Dr Mark Verrill
| A Phase I trial assessing the pharmacokinetics and tolerability of ZD1839 ('Iressa') in hepatically impaired patients with solid tumours | 2002 |
|
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al. | Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study | 2002 |
|
Professor Ruth Plummer
Dr Mark Verrill
| Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced malignancies | 2002 |
|
Dr Andrew Hughes
Dr Paula Calvert
Dr Ashraf Azzabi
Professor Ruth Plummer
Melanie Griffin
et al. | Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma | 2002 |
|
Dr Andrew Hughes
Dr Ashraf Azzabi
Professor Ruth Plummer
Dr Jane Margetts
Kevin Fishwick
et al. | A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate). | 2001 |
|
Dr Mark Verrill
| Anthracyclines in breast cancer: therapy and issues of toxicity | 2001 |
|
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Kevin Fishwick
et al. | Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate | 2001 |
|
Dr Mark Verrill
| Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study | 2000 |
|
Dr Mark Verrill
| Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma | 2000 |
|
Dr Mark Verrill
| Susceptibility of fibromatosis cells in short-term culture to ifosfamide: A possible experimental treatment in clinically aggressive cases | 1999 |
|
